CMV Infection Assessment Using KLRG1 Biomarker Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing cytomegalovirus (CMV) infections in transplant recipients, particularly those who are seronegative but receive seropositive donor tissue, are inadequate in predicting infection control and often result in unnecessary antiviral treatment side effects due to the risk of recurrent CMV reactivation.
Innovation Solution
Assessing the level of KLRG1+/CD8+ T cells in patients to classify them as highly likely, likely, or unlikely to control CMV infection, allowing for tailored treatment approaches that avoid unnecessary antiviral therapy in those who can control the infection and ensure necessary treatment in those who cannot.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral therapy is administered to all transplant recipients at risk for CMV infection, then infection control is improved, but adverse side effects increase due to unnecessary treatment in patients who can control the infection
Solution Approach 1:
The patent changes the parameter of treatment selection from universal to stratified based on KLRG1 expression levels. Patients are divided into high-risk groups (low KLRG1 expression) who receive antiviral therapy and low-risk groups (high KLRG1 expression) who do not, optimizing both infection control and reduction of adverse effects
Solution Approach 2:
The patent enables the patient's immune system to serve itself by identifying patients with high KLRG1+/CD8+ T cell levels who can control CMV infection without medical intervention. These patients' immune responses are sufficient to manage the infection autonomously, eliminating the need for antiviral therapy
2Object-affected harmful factors
If antiviral therapy is avoided in patients likely to control CMV infection, then adverse side effects are reduced, but risk of uncontrolled infection increases in patients who need treatment
Solution Approach 1:
The patent introduces KLRG1 expression level as an intermediary biomarker to mediate the decision between treatment and no treatment. This intermediary allows clinicians to objectively assess immune capacity and make informed decisions, reducing both unnecessary treatment and undertreatment
Solution Approach 2:
The patent performs preliminary assessment of KLRG1 expression levels before initiating treatment decisions. By evaluating immune status in advance, the system determines which patients will need antiviral therapy and which will not, preventing both unnecessary treatment and inadequate protection
3Reliability
If current management methods are used for CMV infection risk, then treatment is provided to all at-risk patients, but measurement precision of infection control prediction is insufficient
Solution Approach 1:
The patent replaces the mechanical/uniform treatment approach with a biologically-informed strategy based on molecular biomarkers. Instead of treating all patients the same way, the system uses KLRG1 expression levels to predict infection control capacity, substituting empirical treatment with precision medicine based on immune phenotype
Data Source
AI summary
This document relates to methods and materials involved in identifying and/or treating mammals having a CMV infection. For example, methods and materials for assessing a mammal having a CMV infection (e.g., a CMV seronegative human who received CMV seropositive donor transplant tissue) to determine if the mammal is likely to control the CMV infection or to determine if the mammal is unlikely to control the CMV infection are provided. Methods and materials for treating a mammal having a CMV infection (e.g., a CMV seronegative human who received CMV seropositive donor transplant tissue) that was either identified as being likely to control the CMV infection or identified as being unlikely to control the CMV infection also are provided.